Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Kentaro Ohki; Ellie R. Butler; Nobutaka Kiyokawa; Shinsuke Hirabayashi; Anke K. Bergmann; Anja Möricke; Judith M. Boer; Hélène Cavé; Giovanni Cazzaniga; Allen Eng Juh Yeoh; Masashi Sanada; Toshihiko Imamura; Hiroto Inaba; Charles G. Mullighan; Mignon L. Loh; Ulrika Norén-Nyström; Lee Yung Shih; Marketa Zaliova; Ching Hon Pui; Oskar A. Haas; Christine J. Harrison; Anthony V. Moorman; Atsushi Manabe

doi:10.1038/s41375-022-01737-4

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Kentaro Ohki, Ellie R. Butler, Nobutaka Kiyokawa, Shinsuke Hirabayashi, Anke K. Bergmann, Anja Möricke, Judith M. Boer, Hélène Cavé, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles G. Mullighan, Mignon L. Loh, Ulrika Norén-Nyström, Lee Yung Shih, Marketa Zaliova, Ching Hon Pui, Oskar A. HaasChristine J. Harrison, Anthony V. Moorman, Atsushi Manabe

Group den Boer

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

7 Citaten (Scopus)

Originele taal-2	Engels
Artikelnummer	10.1038/s41375-022-01737-4
Pagina's (van-tot)	212-216
Aantal pagina's	5
Tijdschrift	Leukemia
Volume	37
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1038/s41375-022-01737-4 https://doi.org/10.1038/s41375-021-01199-0
Status	Gepubliceerd - 2023

Toegang tot document

Citeer dit

Ohki, K., Butler, E. R., Kiyokawa, N., Hirabayashi, S., Bergmann, A. K., Möricke, A., Boer, J. M., Cavé, H., Cazzaniga, G., Yeoh, A. E. J., Sanada, M., Imamura, T., Inaba, H., Mullighan, C. G., Loh, M. L., Norén-Nyström, U., Shih, L. Y., Zaliova, M., Pui, C. H., ... Manabe, A. (2023). Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. Leukemia, 37(1), 212-216. Artikel 10.1038/s41375-022-01737-4. https://doi.org/10.1038/s41375-022-01737-4, https://doi.org/10.1038/s41375-021-01199-0

@article{7314aaa4e4694aa5889716976ea0def6,

title = "Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group",

keywords = "Humans, Retrospective Studies, Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics, Gene Rearrangement, MEF2 Transcription Factors, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics",

author = "Kentaro Ohki and Butler, {Ellie R.} and Nobutaka Kiyokawa and Shinsuke Hirabayashi and Bergmann, {Anke K.} and Anja M{\"o}ricke and Boer, {Judith M.} and H{\'e}l{\`e}ne Cav{\'e} and Giovanni Cazzaniga and Yeoh, {Allen Eng Juh} and Masashi Sanada and Toshihiko Imamura and Hiroto Inaba and Mullighan, {Charles G.} and Loh, {Mignon L.} and Ulrika Nor{\'e}n-Nystr{\"o}m and Shih, {Lee Yung} and Marketa Zaliova and Pui, {Ching Hon} and Haas, {Oskar A.} and Harrison, {Christine J.} and Moorman, {Anthony V.} and Atsushi Manabe",

note = "Funding Information: Research support: We acknowledge funding from Clinical Cancer Research from the Ministry of Health, Labour and Welfare, Japan; Japan Agency for Medical Research and Development (AMED), Japan; Blood Cancer UK (15036); National Cancer Institute (CA021765), US; Czech Health Research Council project NU20-07-00322; ERA-NET TRANSCAN EJC granted by Foundation ARC, France; Center for Biological Resources (CRB-cancer; BB-0033-00076), Robert Debr{\'e} Hospital, France; Oncode Institute and KiKa Foundation, Netherlands; American and Lebanese Syrian Associated Charities of St. Jude Children{\textquoteright}s Research Hospital (HI, CGM, C-HP), US National Cancer Institute R35 CA297695 (CGM). We thank the following additional study group members for their support. AIEOP: Valentino Conter, Andrea Biondi; Polish ALIC: Wojciech Mlynarski; BFM-A: Georg Mann, Andishe Attarbaschi, Karin Nebral, Sabine Strehl and Dagmar Schinnerl; BFM-G/CH: Martin Schrappe; COG: Stephen Hunger; DCOG: Rob Pieters; JACLS: Junichi Hara, Keizo Horibe; NOPHO: Kjeld Schmiegelow, Mats Heyman; TCCSG: Akira Ohara, Katsuyoshi Koh; TPOG: His-Che Liu; CLIP: Jan Stary; UKALL: Ajay Vora, Claire Schwab; SFCE: Chlo{\'e} Arfeuille, Aur{\'e}lie Caye-Eude, Andr{\'e} Baruchel, Yves Bertrand, Pierre Rohrlich, Marion Strullu. Funding Information: CGM: Research support from Loxo, Abbvie, Pfizer. Consulting and speaking fees from Amgen, Illumina. C-HP received consulting and speaker fees from Amgen, Erytech Phamra, and Servier. HI received a research grant from Servier. AVM: Honoria for speaking from Amgen. ",

year = "2023",

doi = "10.1038/s41375-022-01737-4",

language = "English",

volume = "37",

pages = "212--216",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

Ohki, K, Butler, ER, Kiyokawa, N, Hirabayashi, S, Bergmann, AK, Möricke, A, Boer, JM, Cavé, H, Cazzaniga, G, Yeoh, AEJ, Sanada, M, Imamura, T, Inaba, H, Mullighan, CG, Loh, ML, Norén-Nyström, U, Shih, LY, Zaliova, M, Pui, CH, Haas, OA, Harrison, CJ, Moorman, AV & Manabe, A 2023, 'Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group', Leukemia, vol. 37, nr. 1, 10.1038/s41375-022-01737-4, blz. 212-216. https://doi.org/10.1038/s41375-022-01737-4, https://doi.org/10.1038/s41375-021-01199-0

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. / Ohki, Kentaro; Butler, Ellie R.; Kiyokawa, Nobutaka et al.
In: Leukemia, Vol. 37, Nr. 1, 10.1038/s41375-022-01737-4, 2023, blz. 212-216.

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

TY - JOUR

T1 - Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

AU - Ohki, Kentaro

AU - Butler, Ellie R.

AU - Kiyokawa, Nobutaka

AU - Hirabayashi, Shinsuke

AU - Bergmann, Anke K.

AU - Möricke, Anja

AU - Boer, Judith M.

AU - Cavé, Hélène

AU - Cazzaniga, Giovanni

AU - Yeoh, Allen Eng Juh

AU - Sanada, Masashi

AU - Imamura, Toshihiko

AU - Inaba, Hiroto

AU - Mullighan, Charles G.

AU - Loh, Mignon L.

AU - Norén-Nyström, Ulrika

AU - Shih, Lee Yung

AU - Zaliova, Marketa

AU - Pui, Ching Hon

AU - Haas, Oskar A.

AU - Harrison, Christine J.

AU - Moorman, Anthony V.

AU - Manabe, Atsushi

N1 - Funding Information: Research support: We acknowledge funding from Clinical Cancer Research from the Ministry of Health, Labour and Welfare, Japan; Japan Agency for Medical Research and Development (AMED), Japan; Blood Cancer UK (15036); National Cancer Institute (CA021765), US; Czech Health Research Council project NU20-07-00322; ERA-NET TRANSCAN EJC granted by Foundation ARC, France; Center for Biological Resources (CRB-cancer; BB-0033-00076), Robert Debré Hospital, France; Oncode Institute and KiKa Foundation, Netherlands; American and Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital (HI, CGM, C-HP), US National Cancer Institute R35 CA297695 (CGM). We thank the following additional study group members for their support. AIEOP: Valentino Conter, Andrea Biondi; Polish ALIC: Wojciech Mlynarski; BFM-A: Georg Mann, Andishe Attarbaschi, Karin Nebral, Sabine Strehl and Dagmar Schinnerl; BFM-G/CH: Martin Schrappe; COG: Stephen Hunger; DCOG: Rob Pieters; JACLS: Junichi Hara, Keizo Horibe; NOPHO: Kjeld Schmiegelow, Mats Heyman; TCCSG: Akira Ohara, Katsuyoshi Koh; TPOG: His-Che Liu; CLIP: Jan Stary; UKALL: Ajay Vora, Claire Schwab; SFCE: Chloé Arfeuille, Aurélie Caye-Eude, André Baruchel, Yves Bertrand, Pierre Rohrlich, Marion Strullu. Funding Information: CGM: Research support from Loxo, Abbvie, Pfizer. Consulting and speaking fees from Amgen, Illumina. C-HP received consulting and speaker fees from Amgen, Erytech Phamra, and Servier. HI received a research grant from Servier. AVM: Honoria for speaking from Amgen.

PY - 2023

Y1 - 2023

KW - Humans

KW - Retrospective Studies

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics

KW - Gene Rearrangement

KW - MEF2 Transcription Factors

KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics

UR - http://www.scopus.com/inward/record.url?scp=85140974864&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/f2e68d48-8521-3e29-a7bc-5cb408e8a524/

U2 - 10.1038/s41375-022-01737-4

DO - 10.1038/s41375-022-01737-4

M3 - Article

C2 - 36309560

AN - SCOPUS:85140974864

SN - 0887-6924

VL - 37

SP - 212

EP - 216

JO - Leukemia

JF - Leukemia

IS - 1

M1 - 10.1038/s41375-022-01737-4

ER -